Bridged cycloformylpyridine derivatives and uses thereof
US12344611B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2020 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Oct 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided are a compound of formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and a use thereof. The above-mentioned compound has a very strong inhibitory effect on the FGFR4 kinase activity and the proliferative activity of Hep 3B cells with high FGFR4 expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.